Study of Denufosol (INS37217) in Subjects With Rhegmatogenous Retinal Detachment

Exclusion Criteria

• •have a non-rhegmatogenous retinal detachment
• •have large retinal break(s) whose total break area is greater than 1 clock hour in extent
• •have evidence of atrophic retinal pigment epithelium, choroid, choroidal detachment or intraocular inflammation
• •be monocular
• •have a prior retinal detachment repair or a congenital condition that places a greater risk for rhegmatogenous retinal detachment
• •have proliferative vitreoretinopathy greater than grade B
• •have pre-existing subretinal or vitreous hemorrhage, corneal opacity, or other conditions which limit the view of peripheral retina
• •have any co-existing macular pathology or other retinal conditions that can limit visual acuity
• •currently have uncontrollable elevated intraocular pressure, advanced glaucoma, or any history or current evidence of endophthalmitis in the affected eye
• •have symptoms consistent with a rhegmatogenous retinal detachment such as visual disturbance greater than 14 days prior to screening if macula-on OR history of loss of reading vision in affected eye for greater than 6 days prior to screening if macula-off
• •have a retinal detachment with evidence of demarcation lines or evidence of subretinal fibrosis visible upon fundus examination
• •be currently taking medications that could obscure or confound study results including acetazolamide (Diamox) and dorzolamide
• •have had a periocular, retrobulbar or intravitreal injection in the affected eye, including corticosteroids in the 3 months prior to screening or require one